Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Etoposide Phosphate

FDA-approved product (injectable, injection), marketed as Etopophos Preservative Free.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Etoposide Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Lung cancer
  • Lung neoplasm
  • Neoplasm
  • Small cell carcinoma
  • Small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Podophyllotoxin derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Etoposide Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Etoposide Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer

    NCT04675697 · start 2019-01-24

    Registered record
    Registry ID
    NCT04675697
    Conditions
    Extensive-stage Small-cell Lung Cancer
    Interventions
    Platinum-etoposide+Anlotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-01-24
    Completion
    2021-01-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive-stage Small-cell Lung Cancer
    InterventionPlatinum-etoposide+Anlotinib
    PhasePhase 2
    Registry statusUnknown

  • Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer

    NCT02562365 · start 2015-11

    Registered record
    Registry ID
    NCT02562365
    Conditions
    Ovarian Cancer
    Interventions
    Etoposide, Cyclophosphamide, Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-11
    Completion
    2023-11
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionEtoposide, Cyclophosphamide, Carboplatin
    PhasePhase 2
    Registry statusUnknown

  • Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer

    NCT02337712 · start 2015-01

    Registered record
    Registry ID
    NCT02337712
    Conditions
    Small Cell Lung Cancer
    Interventions
    q.d. RT; b.i.d.RT; etoposide and cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2021-12
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Cancer
    Interventionq.d. RT; b.i.d.RT; etoposide and cisplatin
    PhasePhase 2
    Registry statusUnknown

  • Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

    NCT01729845 · start 2012-12-20

    Registered record
    Registry ID
    NCT01729845
    Conditions
    Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia
    Interventions
    Cytarabine; Decitabine; Etoposide; Laboratory Biomarker Analysis; Mitoxantrone Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-12-20
    Completion
    2017-04-03
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreviously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia
    InterventionCytarabine; Decitabine; Etoposide; Laboratory Biomarker Analysis +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer

    NCT01563601 · start 2012-08

    Registered record
    Registry ID
    NCT01563601
    Conditions
    Extensive-stage Small Cell Lung Cancer
    Interventions
    Obatoclax Mesylate, Carboplatine and Etoposide; Carboplatin and Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-08
    Completion
    2018-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive-stage Small Cell Lung Cancer
    InterventionObatoclax Mesylate, Carboplatine and Etoposide; Carboplatin and Etoposide
    PhasePhase 3
    Registry statusWithdrawn

  • A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.

    NCT01236144 · start 2011-04

    Registered record
    Registry ID
    NCT01236144
    Conditions
    Acute Myeloid Leukaemia; High Risk Myelodysplastic Syndrome
    Interventions
    Plerixafor; AC220; Ganetespib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-04
    Completion
    2014-01
    Enrolment
    113

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukaemia; High Risk Myelodysplastic Syndrome
    InterventionPlerixafor; AC220; Ganetespib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

    NCT01092182 · start 2010-03-25

    Registered record
    Registry ID
    NCT01092182
    Conditions
    Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive; Plasmablastic Lymphoma
    Interventions
    EPOCH-R; EPOCH-RR
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03-25
    Completion
    2023-02-16
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive; Plasmablastic Lymphoma
    InterventionEPOCH-R; EPOCH-RR
    PhasePhase 2
    Registry statusCompleted

  • A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

    NCT01084759 · start 2010-03

    Registered record
    Registry ID
    NCT01084759
    Conditions
    Prostate Cancer
    Interventions
    Testosterone injection; Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-03
    Completion
    2014-10
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionTestosterone injection; Etoposide
    PhaseNot applicable
    Registry statusCompleted

  • A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

    NCT00927875 · start 2010-02

    Registered record
    Registry ID
    NCT00927875
    Conditions
    Small Cell Lung Carcinoma
    Interventions
    BMS-833923; Carboplatin; Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-02
    Completion
    2012-09
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Carcinoma
    InterventionBMS-833923; Carboplatin; Etoposide
    PhasePhase 1
    Registry statusCompleted

  • Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia

    NCT01050036 · start 2010-01-11

    Registered record
    Registry ID
    NCT01050036
    Conditions
    Leukemia, Myeloid
    Interventions
    autologous hematopoietic cell transplantation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-01-11
    Completion
    2018-10-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Myeloid
    Interventionautologous hematopoietic cell transplantation
    PhaseNot applicable
    Registry statusCompleted

  • Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

    NCT00967369 · start 2009-08-24

    Registered record
    Registry ID
    NCT00967369
    Conditions
    Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma
    Interventions
    Bortezomib; Carboplatin; Etoposide; Ifosfamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-08-24
    Completion
    2018-05-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma
    InterventionBortezomib; Carboplatin; Etoposide; Ifosfamide
    PhasePhase 2
    Registry statusCompleted

  • New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma

    NCT00933673 · start 2009-06

    Registered record
    Registry ID
    NCT00933673
    Conditions
    Lymphoma
    Interventions
    L-asp, DXM, IFO, VP-16, DDP
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-06
    Completion
    2012-06
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionL-asp, DXM, IFO, VP-16, DDP
    PhasePhase 2
    Registry statusUnknown

  • Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients

    NCT00588835 · start 2008-03

    Registered record
    Registry ID
    NCT00588835
    Conditions
    Tumor
    Interventions
    aprepitant; Dexamethasone and Ondansetron during CE-treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2008-03
    Completion
    2010-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTumor
    Interventionaprepitant; Dexamethasone and Ondansetron during CE-treatment
    PhasePhase 4
    Registry statusTerminated

  • Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

    NCT00513474 · start 2008-01

    Registered record
    Registry ID
    NCT00513474
    Conditions
    Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
    Interventions
    busulfan; cyclophosphamide; cyclosporin-A; etoposide; methotrexate; rasburicase; sirolimus; tacrolimus; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation; fludarabine; allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01
    Completion
    2013-02-12
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma +3 more
    Interventionbusulfan; cyclophosphamide; cyclosporin-A; etoposide +9 more
    PhasePhase 1
    Registry statusCompleted

  • Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

    NCT00567567 · start 2007-11-05

    Registered record
    Registry ID
    NCT00567567
    Conditions
    Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma
    Interventions
    Autologous Hematopoietic Stem Cell Transplantation; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin Hydrochloride; Etoposide; External Beam Radiation Therapy; Filgrastim; Isotretinoin; Laboratory Biomarker Analysis; Melphalan; Peripheral Blood Stem Cell Transplantation; Pharmacological Study; Thiotepa; Topotecan Hydrochloride; Vincristine Sulfate Liposome
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-11-05
    Completion
    2022-03-31
    Enrolment
    665

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocalized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma +2 more
    InterventionAutologous Hematopoietic Stem Cell Transplantation; Carboplatin; Cisplatin; Cyclophosphamide +12 more
    PhasePhase 3
    Registry statusCompleted